Humanigen Forum: Community User: Rothschild123

Mache ich auch immer in Tranchen 👌

Nur bis wohin dieses Dip geht… ehrlich habe mit unter 3 Euro nicht gerechnet

Ich erwarte schon „Dip vor Rip“

Heute nicht mehr… hab gestern wieder verdoppelt

Gestern 🙈

Wir können nur abwarten ;) Hast Du noch nachgekauft?

The company and its management are also expected to meet with investors, analysts, bankers and potential partners during the conferences next week. All presentations and meetings will be held virtually. Dr. Durrant will provide updates on recent interactions with regulatory authorities from the United States, United Kingdom and European Union. Dr. Durrant also will provide updates on the enrollment for the ACTIV-5/BET-B clinical trial of lenzilumab in hospitalized COVID-19 patients (NCT04351152), the strategy and potential timing of an amendment to the Emergency Use Authorization (“EUA”) of lenzilumab for COVID-19 to the U.S. Food and Drug Administration (“FDA”) and the timeline for the response to written questions received from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”). Lastly, Dr. Durrant will describe the company’s clinical development pipeline, including foreign COVID-19 trials with lenzilumab and the studies in CAR-T, aGvHD and CMML.

Morgen wird Webcast verfügbar. Die müssen einfach wegen Partnerschaft was sagen

H.C. Wainwright BIOCONNECT Virtual Conference - January 10 – 13 The prerecorded presentation will be available beginning Monday January 7, 2022, 7:00 AM ET Link to webcast: https://journey.ct.events/view/69fd2a11-6a62-43f3-86a4-17f12adbdda3

MHRA meldet sich nicht… als die auch auf diese Ergebnisse warten würden… für die Aktie gar nicht gut

Bis Ende Q1 wird es weiter so gehen…. Nur bis wohin?🙈🤦🏼‍♀️

Top-line data from ACTIV-5/BET-B expected to be announced late in the first quarter or early in the second quarter of 2022 ACTIV-5/BET-B results to be shared with regulatory authorities in the US, UK, and EU as part of the ongoing review process Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients1

Aktuell keine gute Entwicklung ;)